| CAS NO: | 950455-15-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 340.85 |
|---|---|
| Formula | C19H21ClN4 |
| CAS No. | 950455-15-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 68 mg/mL (199.5 mM) |
| Water: <1 mg/mL | |
| Ethanol: 21 mg/mL (61.6 mM) | |
| SMILES Code | ClC1=CC(CNC(C23CCNCC2)=NC4=C(N3)C=CC=C4)=CC=C1 |
| Synonyms | Liproxstatin-1; Chemical Name: N-[(3-Chlorophenyl)methyl]-spiro[piperidine-4,2′(1′H)-quinoxalin]-3′-amine |
| In Vitro | In vitro activity: Liproxstatin-1 is able to inhibit ferroptosis in the low nanomolar range and inhibit the growth of Gpx4–/–cells with IC50 of 22 nM. Liproxstatin-1 (50 nM) completely prevents lipid peroxidation in Gpx4–/–cells. Liproxstatin-1 (200 nM) protects against FINs, such as BSO (10 μM), erastin (1 μM) and RSL3 (0.5 μM), in a dose dependent manner, whereas it fails to rescue cell death induced by staurosporine (0.2 μM) and H2O2 (200 μM). Kinase Assay: Liproxstatin-1 is a novel, potent inhibitor of ferroptosis with IC50 value of 22 nM in cell free assays. Cell Assay: Cell viability is assessed at different time points after treatment using AquaBluer according to the manufacturer’s recommendations. Alternatively, cell death is also quantified by measuring released lactate dehydrogenase activity using the cytotoxicity detection kit (LDH). |
|---|---|
| In Vivo | Liproxstatin-1 remarkably extends survival compared with the vehicle-treated group, delays ferroptosis in tubular cells, and mitigates tissue injury in ischaemia/reperfusion-induced liver injury. |
| Animal model | GreERT2; Gpx4fI/fI mice |
| Formulation & Dosage | Dissolved in % DMSO in PBS; 10 mg/kg; i.p. injection |
| References | Nat Cell Biol. 2014 Dec;16(12):1180-91. |
m.cnreagent.com